Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Screener
News
About

Home

/

SIBN

S

SI-BONE, Inc. (SIBN)

NGM – Real Time Price. Currency in USD

13.90

+2.29 (19.72%)

At close: May 12, 2026, 4:00 PM EDT

13.95

+0.05 (0.34%)

After-hours: May 12, 2026, 7:57 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript

SiBone Q1 Earnings Call Highlights

SiBone Q1 Earnings Call Highlights

SiBone NASDAQ: SIBN raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahead.

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

Si-Bone (SIBN) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA

First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review

First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review

Leading contributors in the First Eagle Small Cap Opportunity Fund this quarter included Ultra Clean Holdings, Oil States International, Lincoln Educational Services, Advanced Energy and FormFactor. Oil States International shares rallied on very strong bookings during the quarter and improved operator-powered solutions and services inside the wellbore. The leading detractors in the quarter were Vital Farms, Alphatec Holdings, Beta Bionics, SI-BONE. and Herc Holdings.

SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026

SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026

SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Videos

No Data

There is no data to display

Press releases

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance

Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter